ABL1 and acute lymphoblastic leukemia: As illustrated here, we demonstrate that JW patients diagnosed with Ph+ ALL can successfully achieve prolonged overall survival with combinatorial regimens of BCR-ABL TKI, blinatumomab, and low dose chemotherapy supported by liberal growth factor use and hemoglobin alternative.